Blog

Enhancing clinical trials with real-world evidence in pregnancy research

Learn how real-world evidence improves clinical trials in pregnancy by enhancing safety data, trial design,…

CertaraJune 26, 2026

Poster

Mechanistic Modelling of CRS in T-cell Engagers – An Application for Blinatumomab

Discover how Quantitative Systems Pharmacology (QSP) was used to predict cytokine release syndrome risk and…

CertaraJune 23, 2026

Announcement

Certara Integrates D360™ with Secondary Intelligence™ Software to Enhance Predicting Drug Safety Risk

Certara integrates D360 with Secondary Intelligence to help drug researchers identify off-target safety risks earlier…

CertaraJune 12, 2026

Webinar

BioSpace webinar: Streamlining Nonclinical Development with FDA NAMs

CertaraMay 8, 2026

Publication

Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome

A newly approved RNA interference (RNAi) therapy lowers harmful triglyceride (TG) levels in patients with…

CertaraMay 7, 2026

Publication

Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

This study evaluated how the leukemia drug ziftomenib behaves in the body and whether different…

CertaraMay 7, 2026

Publication

Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies

Population pharmacokinetic (PopPK) and exposure-response modeling were used to support the clinical development of nemtabrutinib,…

CertaraMay 7, 2026

Blog

ADC Dose Optimization: Applying Model-Informed Strategies in Development

Explore ADC dose optimization using model-informed strategies to balance efficacy and safety across antibody drug…

CertaraApril 22, 2026

Publication

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

This study demonstrates how a model-informed, totality-of-evidence approach was used to select the optimal clinical…

Danielle PillsburyApril 2, 2026

Publication

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

This review article examines the development of radiopharmaceutical imaging agents and radioligand therapies for pediatric…

CertaraMarch 26, 2026

Drug Safety

Enhancing clinical trials with real-world evidence in pregnancy research

Mechanistic Modelling of CRS in T-cell Engagers – An Application for Blinatumomab

Certara Integrates D360™ with Secondary Intelligence™ Software to Enhance Predicting Drug Safety Risk

BioSpace webinar: Streamlining Nonclinical Development with FDA NAMs

Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome

Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies

ADC Dose Optimization: Applying Model-Informed Strategies in Development

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

Newsletter sign up

Quick links

Solutions

Contact